Annexon (ANNX) Competitors $2.81 -0.02 (-0.71%) Closing price 04:00 PM EasternExtended Trading$2.89 +0.08 (+2.85%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ANNX vs. SNDX, ARVN, ANIP, DAWN, ADPT, RCUS, CALT, SYRE, SPRY, and OCULShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Syndax Pharmaceuticals (SNDX), Arvinas (ARVN), ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), Adaptive Biotechnologies (ADPT), Arcus Biosciences (RCUS), Calliditas Therapeutics AB (publ) (CALT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Syndax Pharmaceuticals Arvinas ANI Pharmaceuticals Day One Biopharmaceuticals Adaptive Biotechnologies Arcus Biosciences Calliditas Therapeutics AB (publ) Spyre Therapeutics ARS Pharmaceuticals Ocular Therapeutix Syndax Pharmaceuticals (NASDAQ:SNDX) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership. Does the media refer more to SNDX or ANNX? In the previous week, Annexon had 10 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 16 mentions for Annexon and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.51 beat Annexon's score of 0.42 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, SNDX or ANNX? Syndax Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Which has better earnings and valuation, SNDX or ANNX? Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax PharmaceuticalsN/AN/A-$209.36M-$3.63-4.51AnnexonN/AN/A-$134.24M-$1.05-2.68 Is SNDX or ANNX more profitable? Annexon's return on equity of -38.99% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax PharmaceuticalsN/A -64.34% -57.72% Annexon N/A -38.99%-33.90% Do analysts recommend SNDX or ANNX? Syndax Pharmaceuticals presently has a consensus price target of $36.20, suggesting a potential upside of 121.00%. Annexon has a consensus price target of $15.80, suggesting a potential upside of 462.28%. Given Annexon's stronger consensus rating and higher possible upside, analysts plainly believe Annexon is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Annexon 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor SNDX or ANNX? Syndax Pharmaceuticals received 333 more outperform votes than Annexon when rated by MarketBeat users. However, 77.14% of users gave Annexon an outperform vote while only 65.37% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyndax PharmaceuticalsOutperform Votes38765.37% Underperform Votes20534.63% AnnexonOutperform Votes5477.14% Underperform Votes1622.86% SummaryAnnexon beats Syndax Pharmaceuticals on 10 of the 13 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.05M$7.07B$5.80B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-2.686.0226.3218.88Price / SalesN/A316.05452.0876.91Price / CashN/A67.8344.0437.47Price / Book0.886.757.644.66Net Income-$134.24M$138.11M$3.18B$245.69M7 Day Performance-8.31%-1.85%-1.66%-2.22%1 Month Performance-32.49%-1.39%0.41%-1.95%1 Year Performance-42.67%-2.92%17.47%14.12% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.5518 of 5 stars$2.81-0.7%$15.80+462.3%-45.5%$299.52MN/A-2.6860News CoverageGap UpSNDXSyndax Pharmaceuticals3.7342 of 5 stars$14.92-1.1%$36.20+142.6%-30.1%$1.27BN/A-4.11110ARVNArvinas3.0934 of 5 stars$18.31+3.6%$60.00+227.7%-63.7%$1.26B$78.50M-3.92420Gap UpANIPANI Pharmaceuticals4.3778 of 5 stars$58.92-0.5%$77.71+31.9%+2.3%$1.24B$486.82M-107.13600DAWNDay One Biopharmaceuticals2.1092 of 5 stars$12.26+0.4%$35.71+191.3%-17.9%$1.24B$101.95M-11.9060Upcoming EarningsInsider TradeNews CoverageADPTAdaptive Biotechnologies3.6449 of 5 stars$8.33-2.2%$8.30-0.4%+116.4%$1.23B$170.28M-6.22790Analyst ForecastInsider TradeRCUSArcus Biosciences2.7514 of 5 stars$13.05+2.8%$32.67+150.3%-35.2%$1.19B$117M-4.14500Analyst ForecastAnalyst RevisionNews CoverageGap UpCALTCalliditas Therapeutics AB (publ)0.1154 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180SYRESpyre Therapeutics2.0845 of 5 stars$22.92+1.1%$54.83+139.2%+2.1%$1.18B$890,000.00-3.07100Analyst UpgradeNews CoverageSPRYARS Pharmaceuticals3.199 of 5 stars$12.02+0.8%$28.80+139.6%+56.6%$1.17B$30,000.00-23.5790Analyst ForecastNews CoverageGap UpOCULOcular Therapeutix3.4059 of 5 stars$7.28-2.7%$17.00+133.5%-3.6%$1.14B$58.44M-5.52230 Related Companies and Tools Related Companies SNDX Competitors ARVN Competitors ANIP Competitors DAWN Competitors ADPT Competitors RCUS Competitors CALT Competitors SYRE Competitors SPRY Competitors OCUL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANNX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
